We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

139 hedge funds and large institutions have $969M invested in ArriVent BioPharma in 2026 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

245% more call options, than puts

Call options by funds: $12.3M | Put options by funds: $3.56M

112% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 17

104% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 28

20% more capital invested

Capital invested by funds: $810M → $969M (+$159M)

15% more funds holding

Funds holding: 121 → 139 (+18)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

1.92% less ownership

Funds ownership: 97.14% → 95.22% (-1.9%)

Holders
139
Holders Change
+18
Holders Change %
+14.88%
% of All Funds
1.71%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
36
Increased
57
Reduced
28
Closed
17
Calls
$12.3M
Puts
$3.56M
Net Calls
+$8.72M
Net Calls Change
+$1.3M

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$20M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$8.66M
4
LGM
Logos Global Management
California
+$7.9M
5
State Street
State Street
Massachusetts
+$7.44M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$15.5M
2
ACM
AIHC Capital Management
-$13M
3
Citadel Advisors
Citadel Advisors
Florida
-$6.6M
4
RA
Rosalind Advisors
Ontario, Canada
-$4.88M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$4.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
AF
126
Allworth Financial
California
$1.04K +$610 +27 +150%
Royal Bank of Canada
127
Royal Bank of Canada
Ontario, Canada
$1K -$21.2K -937 -96%
TM
128
Torren Management
California
$761 – – –
CIAM
129
Caitong International Asset Management
Hong Kong
$715 -$17.5K -776 -96%
EWA
130
EverSource Wealth Advisors
Alabama
$623 +$361 +16 +145%
SS
131
SBI Securities
Japan
$600 -$452 -20 -43%
PA
132
Parallel Advisors
California
$554 +$542 +24 New
RIL
133
Rothschild Investment LLC
Illinois
$531 +$68 +3 +15%
MCM
134
MAI Capital Management
Ohio
$439 +$429 +19 New
RFP
135
Root Financial Partners
California
$415 +$407 +18 New
EP
136
Essential Partners
California
$185 +$158 +7 +700%
TWD
137
True Wealth Design
Ohio
$139 +$45 +2 +50%
KFAS
138
Keating Financial Advisory Services
Kansas
$23 +$23 +1 New
ACM
139
AIHC Capital Management
– -$13M -644,788 Closed
RA
140
Rosalind Advisors
Ontario, Canada
– -$4.88M -215,871 Closed
HLAM
141
Hidden Lake Asset Management
New York
– -$3.07M -152,448 Closed
Simplex Trading
142
Simplex Trading
Illinois
– -$1.03M -45,558 Closed
Two Sigma Advisers
143
Two Sigma Advisers
New York
– -$746K -37,100 Closed
AFM
144
Anson Funds Management
Texas
– -$712K -35,366 Closed
NIM
145
NEOS Investment Management
Connecticut
– -$654K -32,487 Closed
TE
146
Tema ETFs
New York
– -$644K -32,007 Closed
Walleye Capital
147
Walleye Capital
New York
– -$445K -22,115 Closed
BHCM
148
Brevan Howard Capital Management
Jersey
– -$335K -16,635 Closed
VF
149
Virtu Financial
New York
– -$227K -11,300 Closed
Group One Trading
150
Group One Trading
Illinois
– -$64.5K -2,854 Closed
3 4 5
6
7

AVBP Hedge Fund Activity: Q1 2026 in Review

139 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q1 2026, worth a combined $969M — up 20% from $810M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new AVBP positions and 17 closed out — a net gain of 19 holders — while 57 added to existing stakes and 28 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $20M. The largest seller was Fidelity Investments, cutting an estimated $15.5M.

  • 139 institutional investors held ArriVent BioPharma (AVBP) as of Q1 2026, up from 121 in Q4 2025.
  • Funds reported $969M of ArriVent BioPharma stock for Q1 2026, up 20% quarter-over-quarter.
  • 36 funds opened new ArriVent BioPharma positions in Q1 2026 and 17 closed out, a net change of +19 holders.
  • The largest ArriVent BioPharma buyer in Q1 2026 was Vivo Capital, an estimated $20M added.
  • The largest ArriVent BioPharma seller in Q1 2026 was Fidelity Investments, an estimated $15.5M sold.

Based on aggregated 13F filings for Q1 2026.